Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1

Liang Huang, Chi-Fei Wang, Charles N. Serhan, Gary Strichartz

研究成果: Article

67 引文 (Scopus)

摘要

Postoperative pain slows surgical recovery, impacting the return of normal function for weeks, months, or longer. Here we report the antihyperalgesic actions of a new compound, resolvin D1 (RvD1), known to reduce inflammation and to suppress pain after peripheral nerve injury, on the acute pain occurring after paw incision and the prolonged pain after skin-muscle retraction. Injection of RvD1 (20-40 ng) into the L5-L6 intrathecal space 30 minutes before surgery reduces the postincisional primary mechanical hypersensitivity, lowering the peak change by approximately 70% (with 40 ng) and reducing the area under the curve (AUC) for the entire 10-day postincisional course by approximately 60%. Intrathecal injection of RvD1 on postoperative day (POD) 1 reduces the hyperalgesia to the same level as that from preoperative injection within a few hours, an effect that persists for the remaining PODs. Tactile allodynia and hyperalgesia following the skin/muscle incision retraction procedure, measured at the maximum values 12 to 14 days, is totally prevented by intrathecal RvD1 (40 ng) given at POD 2. However, delaying the injection until POD 9 or POD 17 results in RvD1 causing only transient and incomplete reversal of hyperalgesia, lasting for <1 day. These findings demonstrate the potent, effective reduction of postoperative pain by intrathecal RvD1 given before or shortly after surgery. The much more limited effect of this compound on retraction-induced pain, when given 1 to 2 weeks later, suggests that the receptors or pathways for resolvins are more important in the early than the later stages of postoperative pain. Single intrathecal injections of resolvin D1 in rats before or 1 to 2 days after surgery strongly reduce postoperative pain for several weeks.

原文English
頁(從 - 到)557-565
頁數9
期刊Pain
152
發行號3
DOIs
出版狀態Published - 2011 三月 1

指紋

Postoperative Pain
Hyperalgesia
Spinal Injections
Pain
Injections
Peripheral Nerve Injuries
Muscles
Skin
Acute Pain
resolvin D1
Ambulatory Surgical Procedures
Area Under Curve
Hypersensitivity
Inflammation

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

引用此文

Huang, Liang ; Wang, Chi-Fei ; Serhan, Charles N. ; Strichartz, Gary. / Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1. 於: Pain. 2011 ; 卷 152, 編號 3. 頁 557-565.
@article{917b4722c75a4b348270d5fa3cc8285a,
title = "Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1",
abstract = "Postoperative pain slows surgical recovery, impacting the return of normal function for weeks, months, or longer. Here we report the antihyperalgesic actions of a new compound, resolvin D1 (RvD1), known to reduce inflammation and to suppress pain after peripheral nerve injury, on the acute pain occurring after paw incision and the prolonged pain after skin-muscle retraction. Injection of RvD1 (20-40 ng) into the L5-L6 intrathecal space 30 minutes before surgery reduces the postincisional primary mechanical hypersensitivity, lowering the peak change by approximately 70{\%} (with 40 ng) and reducing the area under the curve (AUC) for the entire 10-day postincisional course by approximately 60{\%}. Intrathecal injection of RvD1 on postoperative day (POD) 1 reduces the hyperalgesia to the same level as that from preoperative injection within a few hours, an effect that persists for the remaining PODs. Tactile allodynia and hyperalgesia following the skin/muscle incision retraction procedure, measured at the maximum values 12 to 14 days, is totally prevented by intrathecal RvD1 (40 ng) given at POD 2. However, delaying the injection until POD 9 or POD 17 results in RvD1 causing only transient and incomplete reversal of hyperalgesia, lasting for <1 day. These findings demonstrate the potent, effective reduction of postoperative pain by intrathecal RvD1 given before or shortly after surgery. The much more limited effect of this compound on retraction-induced pain, when given 1 to 2 weeks later, suggests that the receptors or pathways for resolvins are more important in the early than the later stages of postoperative pain. Single intrathecal injections of resolvin D1 in rats before or 1 to 2 days after surgery strongly reduce postoperative pain for several weeks.",
author = "Liang Huang and Chi-Fei Wang and Serhan, {Charles N.} and Gary Strichartz",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.pain.2010.11.021",
language = "English",
volume = "152",
pages = "557--565",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "3",

}

Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1. / Huang, Liang; Wang, Chi-Fei; Serhan, Charles N.; Strichartz, Gary.

於: Pain, 卷 152, 編號 3, 01.03.2011, p. 557-565.

研究成果: Article

TY - JOUR

T1 - Enduring prevention and transient reduction of postoperative pain by intrathecal resolvin D1

AU - Huang, Liang

AU - Wang, Chi-Fei

AU - Serhan, Charles N.

AU - Strichartz, Gary

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Postoperative pain slows surgical recovery, impacting the return of normal function for weeks, months, or longer. Here we report the antihyperalgesic actions of a new compound, resolvin D1 (RvD1), known to reduce inflammation and to suppress pain after peripheral nerve injury, on the acute pain occurring after paw incision and the prolonged pain after skin-muscle retraction. Injection of RvD1 (20-40 ng) into the L5-L6 intrathecal space 30 minutes before surgery reduces the postincisional primary mechanical hypersensitivity, lowering the peak change by approximately 70% (with 40 ng) and reducing the area under the curve (AUC) for the entire 10-day postincisional course by approximately 60%. Intrathecal injection of RvD1 on postoperative day (POD) 1 reduces the hyperalgesia to the same level as that from preoperative injection within a few hours, an effect that persists for the remaining PODs. Tactile allodynia and hyperalgesia following the skin/muscle incision retraction procedure, measured at the maximum values 12 to 14 days, is totally prevented by intrathecal RvD1 (40 ng) given at POD 2. However, delaying the injection until POD 9 or POD 17 results in RvD1 causing only transient and incomplete reversal of hyperalgesia, lasting for <1 day. These findings demonstrate the potent, effective reduction of postoperative pain by intrathecal RvD1 given before or shortly after surgery. The much more limited effect of this compound on retraction-induced pain, when given 1 to 2 weeks later, suggests that the receptors or pathways for resolvins are more important in the early than the later stages of postoperative pain. Single intrathecal injections of resolvin D1 in rats before or 1 to 2 days after surgery strongly reduce postoperative pain for several weeks.

AB - Postoperative pain slows surgical recovery, impacting the return of normal function for weeks, months, or longer. Here we report the antihyperalgesic actions of a new compound, resolvin D1 (RvD1), known to reduce inflammation and to suppress pain after peripheral nerve injury, on the acute pain occurring after paw incision and the prolonged pain after skin-muscle retraction. Injection of RvD1 (20-40 ng) into the L5-L6 intrathecal space 30 minutes before surgery reduces the postincisional primary mechanical hypersensitivity, lowering the peak change by approximately 70% (with 40 ng) and reducing the area under the curve (AUC) for the entire 10-day postincisional course by approximately 60%. Intrathecal injection of RvD1 on postoperative day (POD) 1 reduces the hyperalgesia to the same level as that from preoperative injection within a few hours, an effect that persists for the remaining PODs. Tactile allodynia and hyperalgesia following the skin/muscle incision retraction procedure, measured at the maximum values 12 to 14 days, is totally prevented by intrathecal RvD1 (40 ng) given at POD 2. However, delaying the injection until POD 9 or POD 17 results in RvD1 causing only transient and incomplete reversal of hyperalgesia, lasting for <1 day. These findings demonstrate the potent, effective reduction of postoperative pain by intrathecal RvD1 given before or shortly after surgery. The much more limited effect of this compound on retraction-induced pain, when given 1 to 2 weeks later, suggests that the receptors or pathways for resolvins are more important in the early than the later stages of postoperative pain. Single intrathecal injections of resolvin D1 in rats before or 1 to 2 days after surgery strongly reduce postoperative pain for several weeks.

UR - http://www.scopus.com/inward/record.url?scp=79851510275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851510275&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2010.11.021

DO - 10.1016/j.pain.2010.11.021

M3 - Article

C2 - 21255928

AN - SCOPUS:79851510275

VL - 152

SP - 557

EP - 565

JO - Pain

JF - Pain

SN - 0304-3959

IS - 3

ER -